Moderna, Inc. (MRNA)

AI-powered earnings prediction for Moderna, Inc. (MRNA).

49.87
+0.34%
USD, 2 days ago
Market Cap
19.24B
Google

Company Overview

Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company's respiratory vaccines include spikevax, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, such as lyme vaccines. It also provides oncology therapeutics, such as individualized neoantigen and checkpoint adaptive immune modulation therapy; and rare disease products, including propionic and methylmalonic acidemia, glycogen storage disease type 1a, ornithine transcarbamylase deficiency, phenylketonuria, crigler-najjar syndrome type 1, and cystic fibrosis. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Generation Bio Co.; immatics N.V.; Life Edit Therapeutics; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; The Bill & Melinda Gates Foundation; and OpenAI. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Sector
Healthcare
Industry
Biotechnology
Phone
617 714 6500
Headquarters
325 Binney Street
Cambridge, MA, 02142
United States

Key Metrics

Forward P/E
-10.69
Price to Book
2.23
Beta
1.34
Profit Margin
-145.16%
Gross Margin
-105.76%
Return on Equity
-28.87%
Return on Assets
-14.51%
Earnings Growth
N/A
Revenue Growth
-29.80%

Financial Health

Total Cash
$5.80B
Total Debt
$1.26B
Debt to Equity
14.60
Current Ratio
3.29
Free Cash Flow
$-1278249984.00
Operating Cash Flow
$-1872999936.00

Analyst Recommendations

Target Price (Mean)
$41.75
Target High
$135.00
Target Low
$12.00
Recommendation
hold
Analyst Coverage
20 Analysts

Trading Ideas

Related Stocks